Kornimate/medical-research-clean huggingface dataset:
lung ultrasound in neonatal intensive care units

Conditions: Neonatal Respiratory Distress

Summary: identification of lung diseases causing neonatal respiratory distress by lung ultrasound as a tool that can replace x-ray .

* lung disease is the most common cause of neonatal respiratory distress. * it can result in respiratory failure and death in severe cases. * the mortality rate is approximately 11%:32%. * identification of the etiology of lung disease is important for neonatologists. * traditionally, chest x-ray has been considered as the most valuable imaging modality for the diagnosis of lung diseases, but it unavoidably causes radiation damage to the patient. * neonates are susceptible to radiation because they have rapidly dividing cells that cannot repair mutated dna. * the risk of cancer induction in infants receiving a single small dose of radiation is 2-3 times higher than the average population and 6-9 times higher than the risk from an exposure of a 60-year-old patient. * new imaging modalities have been introduced in clinical practice in recent years such as lung ultrasound. * one of the most common causes of neonatal respiratory distress that can be diagnosed by ultrasound is :respiratory distress syndrome: * respiratory distress syndrome.. is a major cause of neonatal mortality. * it mainly occur in preterm infants due to structural and functional lung immaturity. * pulmonary surfactant insufficiency is an important pathogenesis in respiratory distress syndrome. * the ultrasonic features of respiratory distress syndrome are: compact b-lines, white lung appearance, abnormality in pleural line (thick and irregular),lung consolidation. * lung ultrasound has the advantages of : * non-ionizing. * easy to operate. * low coast. * portable for bedside use. * the imaging is performed in real-time. * thus making it as a potential tool to be used in neonatal intensive care units.

Eligibility criteria:
inclusion criteria: * neonates in neonatal intensive care units exclusion criteria: * patients with poor-quality of lung ultrasound image. * subcutaneous emphysema.
intrathecal rituximab with standard intrathecal prophylaxis to prevent cns relapse for cd 20+ non hodgkin lymphoma

Conditions: Non Hodgkin Lymphoma

Summary: the purpose of this research study is to learn if giving rituximab, the study drug, right into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.


Eligibility criteria:
inclusion criteria: * cd20 positive diffuse large b-cell lymphoma undergoing treatment with systemic rituximab in combination with chop, choep, or epoch and deemed high risk of cns relapse and eligible for central nervous system prophylaxis with intrathecal therapy. exclusion criteria: * primary central nervous system lymphoma or established secondary central nervous system disease. * history of spinal surgery and/or ineligible for intrathecal injections.
activity counseling trial (act)

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to develop and evaluate the effectiveness of various intervention approaches, delivered in primary health-care settings, in increasing and maintaining habitual physical activity and cardiorespiratory fitness among sedentary men and women patients.

background: a conference on physical activity sponsored by the national heart, lung, and blood institute (nhlbi) in august 1991 recommended that one priority area for research should be the development and evaluation of interventions for adoption and maintenance of physical activity including interventions that can be incorporated into primary care practice. the 1992 nhlbi working group report on primary prevention of hypertension identified physical inactivity as a risk factor for hypertension. intervention research applicable to health-care settings is particularly important in light of national recommendations advising health-care professionals to intervene, including healthy people 2000, the u.s. preventive services task force reports, and the american heart association. design narrative: randomized, multicenter, demonstration and education study. men and women primary care patients at three sites in dallas, palo alto, and memphis were randomized to two patient education intervention groups or to a standard care control group of physician advice. intervention continued for two years for all participants. the primary outcomes were cardiorespiratory fitness and physical activity. other outcomes were effects on blood pressure, lipoproteins, and weight; the long-term maintenance of these effects; and the cost-effectiveness of various intervention approaches. recruitment took 15 months and has been completed with the accrual of 874 subjects. the national institute on aging participated in the act through the addition of a measurement of arterial stiffness involving approximately 700 patients. the nia tested the hypothesis that increases in physical activity resulting from educational interventions could reduce arterial stiffness.

Eligibility criteria:
sedentary men and women, free of coronary heart disease, who were patients in primary care settings.
study the effect of neurectomy of nasopalatine nerve on sensation of anterior palate

Conditions: Missing Teeth

Summary: study the effect of neurectomy of nasopalatine nerve on the sensation of anterior palate in patients undergoing rehabilitation of anterior maxillary ridge with dental implant

replacement of missing teeth in the anterior maxilla could be challenging if enlargement of the nasopalatine canal which is located in the midline of the palate posterior to the maxillary central incisors or ridge atrophy occur after tooth extraction. this could place the neurovascular content of the nasopaltine canal in the path of the dental implant which may lead to complications such as nasopalatine canal cyst, sensory dysfunction or implant failure. technique to overcome this problem have evolved including neurectomy of the nasopalatine canal content and obliteration of canal with bone graft. loss of sensation in anterior palate following this procedure could be an annoying complication for patients. in recent studies regaining of sensation following such procedure have been reported, confirmation of such results is essential to rule out the side effect of loss of sensation in the anterior palatal region

Eligibility criteria:
inclusion criteria: * • adult patients requiring dental implants placement in the anterior region of maxilla and has insufficient horizontal bone . * patients should be free from any systemic conditions that may affect soft tissue healing. exclusion criteria: * • patients with systematic disease that may complicate healing. * uncontrolled diabetic patient. * patients with advanced osteoporosis. * patients under bisphosphonates treatment. * patients with neurological disorders (neuralgias, parkinson's disease). * patients with horizontal ridge atrophy (if the horizontal dimension of the residual ridge \<3mm as determined with ridge callipers). * heavy smoker patients.
intraoperative radiotherapy for early stage breast cancer

Conditions: Breast Cancer

Summary: up to 200 patients with biopsy proven early stage breast cancer selecting wide local excision (wle) will undergo mammography, ultrasound (of affected breast and ipsilateral axilla) and contrast enhanced-magnetic resonance imaging (ce-mri) of the affected breast to evaluate the extent of disease.

patients will be deemed eligible for immediate iort if the invasive cancer lesion is estimated to measure ≤ 3.0 centimeters maximum dimension by mammogram, ultrasound, and ce-mri and is thought to be resectable with wle and clear surgical margins, with clinically staged n0m0 disease, minimum age of 48, and histology of invasive ductal or lobular carcinoma of the breast. the lesion size determined by imaging will be compared with lesion size and surgical margin status obtained from the surgical pathology specimen to evaluate the ability of mammography combined with ultrasound and ce-mri to identify suitable candidates for immediate iort.

Eligibility criteria:
inclusion criteria: 1. informed consent. each eligible patient must willingly give written consent after being informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts. 2. histology. patients must have biopsy-proven invasive ductal or lobular carcinoma of the breast. 3. female, age ≥ 48 years. 4. clinically and/or histologically negative axillary lymph nodes. 5. no imaging or clinical findings that indicate metastatic disease. 6. procedure deemed appropriate based upon factors such as breast size by the treating surgeon and radiation oncologist. exclusion criteria: 1. male sex 2. age \< 48 3. non-epithelial breast malignancies such as sarcoma, lymphoma, or metastatic breast cancer 4. pregnancy or lactation 5. serious psychiatric or addictive disorders 6. more than one obvious cancer in the same breast as diagnosed by clinical examination, mammography, ultrasonography, and/or ce-mri. 7. bilateral breast cancer at the time of diagnosis, unless agreed upon by the surgeon and radiation oncologist. 8. ipsilateral breast with a previous cancer and/or irradiation. 9. extensive intraductal component (dcis ≥ 25% of the tumor). 10. patients presenting with gross nodal disease considered to be clinically malignant by scanning or proven cytologically or by sentinel node biopsy will be cancelled. 11. previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years is 90% or greater. 12. lymphovascular invasion on needle biopsy. 13. patients undergoing primary medical treatment (hormones or chemotherapy) as initial treatment with intent to reduce tumor size.

Keywords: breast iort electronic brachytherapy
guidance in diet and physical activity for prevention of weight gain after gastric bypass surgery

Conditions: Obesity

Summary: primary outcomes: 1. to study cross-sectional associations between diet, physical activity, t2dm and weight in subjects 2 yrs after surgery. 2. to study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group. secondary outcomes: 3. to study the association between vit.d levels and t2dm. 4. to study the association between weight change and qol. 5. to validate the new guidance strategy by recording food intake, energy expenditure and physical activity level. 6. to study if subjects receiving extra guidance in diet and physical activity experience other health effects compared to a control group. 7. to search for biomarkers that can identify people at risk of increasing weight post surgery

expected weight loss after gbp is 60-80% of the overweight. gbp is effective therapy against the obesity-related disorders, including t2dm. some subjects start gaining weight within 12-18 months after surgery. weight gain may again increase the risk for developing obesity-related disorders. previous studies have found a link between vitamin d deficiencies and t2dm. vitamin d levels will be monitored during the intervention. studies have shown that patients who underwent gbp experienced a dramatic improvement in quality of life(qol). after reaching maximum weight loss, many will slowly gain weight. for some people that means a decrease in qol. in order to prevent weight gain it may be useful to provide additional follow-ups. participants are randomised into two groups: group a will receive extra guidance and follow-up, while group b will continue with the existing scheme. participants in group a will over the next 2 yrs take part in frequent meetings. to assess dietary habits, physical activity patterns and qol, food diaries, physical activity questionnaires and qol questionnaires are used. anthropometric and blood pressure measurements will be taken and blood samples will be collected at regular time intervals before and during the study. the results will be used to validate the effect of extra guidance, and to decide if this treatment shall be offered to all of our patients.

Eligibility criteria:
inclusion criteria: * patients undergoing gastric bypass surgery at ouh in the period january 2006 to june 2009 (recruited 24 ± 9 months following surgery) * willingness to participate at regular meetings at ouh exclusion criteria: * patients who have experienced serious complications due to the bariatric surgery * patients who do not understand norwegian * immobile patients

Keywords: weight maintenance group counseling prevention of diseases
a study of ixekizumab (ly2439821) versus adalimumab in participants with psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: the main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (psa) who are biologic disease-modifying anti-rheumatic drugs (dmard) naive.


Eligibility criteria:
inclusion criteria: * presence of established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets classification for psoriatic arthritis (caspar) criteria * active psa defined as the presence of at least 3 (out of 68) tender and at least 3 (out of 66) swollen joints * presence of active plaque psoriasis with a bsa ≥3% * men must agree to use a reliable method of birth control or remain abstinent during the study * women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment * have had an inadequate response when treated with 1 or more conventional synthetic disease-modifying antirheumatic drugs (csdmards) exclusion criteria: * current or prior use of biologic agents for treatment of ps or psa * evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than psa * have participated in any study with interleukin 17 (il-17) antagonists, including ixekizumab * serious disorder or illness other than psoriatic arthritis * serious infection within the last 3 months * active crohn's disease or active ulcerative colitis * active vasculitis or uveitis * diagnosis of or history of malignant disease \<5 years prior to randomization * women who are breastfeeding
sciatic block increases regional saturation in peripheral artery occlusive disease.

Conditions: Peripheral Artery Occlusive Disease; Popliteal Sciatic Nerve Block

Summary: we conducted single-center prospective observational study to evaluate the improvement of peripheral vascular perfusion monitored with near-infrared spectroscopy, in patients undergoing endovascular surgery after performing sciatic nervous block.

the aims of that study is to check regional oxigen saturation variability in patients suffering from peripheral artery occlusive disease (iia to iii fontaine classification) undergoing popliteal sciatic nerve block as analgesic procedure before vascular surgery. we want to evaluate the increase in regional microcirculation after the popliteal nerve blocks due to vasoplegic response and vasodilatation after performing regional anaesthesia. we will place nirs electrode on the instep of the foot to evaluate regional oxigen saturation in the interested leg before the performing of popliteal sciatic nerve block and then during the surgery (after 5 minuts, 15 minuts, 30 minuts), and after the end of the procedure.

Eligibility criteria:
inclusion criteria: * age: \> 18 years * peripheral artery occlusive desease involving popliteal, tibial and/or peroneal artery * stadiation iia to iii in fontaine classification * eligibility for pta or stenting exclusion criteria: * trophic alteration of the application site of the nirs * less than 18 years * pregnancy * need of sedation during the procedure * revascularization performed as emergency surgery * allergic reactions with local anaesthetic * previous surgery involving the interested artery

Keywords: regional oxigen saturation
risk factors and outcomes of immune-mediated encephalitis following exposure to nivolumab

Conditions: Encephalitis

Summary: a case series analysis of encephalitis events reported to the sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.


Eligibility criteria:
inclusion criteria: * moderate, severe, life-threatening or fatal encephalitis events occurring in patients treated with nivolumab and reported to the sponsor exclusion criteria: * encephalitis cases identified through literature reviews and not reported to the sponsor * encephalitis cases identified from company-sponsored observational studies with secondary data collection * spontaneous reports not submitted directly to the sponsor other protocol-defined inclusion/exclusion criteria apply
keeping oral o parental anticoagulation in the acute phase of cardioembolic ischemic stroke

Conditions: Cardioembolic Stroke; Anticoagulant Therapy; Stroke Recurrence; Haemorrhagic Transformation Stroke

Summary: this is an observational, prospective, multicenter, cohort study in patients with cardioembolic stroke and previous oral or parenteral anticoagulant therapy. patients in which anticoagulante therapy is mantained will be compared to those in which it is interrupted, in terms of stroke or systemic embolism and haemorrhagic transformation.

observational, prospective, multicenter, cohort study in patients with recent cardioembolic stroke (\<24 hours) and previous oral or parenteral anticoagulant therapy (last dose recieved \<24hours) . patients in which anticoagulante therapy is mantained will be compared to those in which it is interrupted. the decision to mantain or interrumpt the anticoagulant therapy is made by the treating physician as hospital protocol. stroke recurrence, haemorrhagic transformation at 90 days are evalauted and also complication during the hospitalization and functional outcome.

Eligibility criteria:
inclusion criteria: * ischemic stroke of less than 24 hours since beginning of symptoms or last seen normal * mayor cardioembolic source (atrial fibrilation or flutter, mechanical heart valve prosthesis, recient miocardic infarction, rheumatic mitral valve stenosis, dilated cardiomyopathy, atrial myxoma, left ventricular focal akynesia. * previous treatment with oral anticoagulants (vitamin k antagonists or direct oral anticoagulants), having received the last dose within the previous 24 hours. treatment with intravenous or subcutaneos heparin is also valid. * age \>18 years-old * signed informed consent (by patient or representative) exclusion criteria: * history of intracraneal or extracraneal haemorrhage that contraindicates anticoagulant therapy * patients treated with intravenous thrombolysis as a reperfusion therapy * intracraneal haemorrhage on initial ct scan * health status with a short survival prevision * patients in which a neurosurgery intervention could be indicated * child-bearing woman or in breast-feeding period.
a clinical trial to evaluate the efficacy and safety of dr-2011 for in vitro fertilization

Conditions: Infertility

Summary: this is a multi-center study to evaluate the effects of dr-2011 compared to a progesterone gel in women undergoing in vitro fertilization with fresh eggs. the overall study duration will be approximately 12 months and will involve ovarian suppression/stimulation protocols as well as egg retrieval.


Eligibility criteria:
inclusion criteria: * pre-menopausal, aged 18-42 old at time of consent * at least one cycle without fertility medication prior to screening * tubal, idiopathic, male factor, ovulatory dysfunction or endometriosis- linked infertility * semen analysis (frozen sperm, including donor sperm, may be used, as long as testing done at time of freezing meets standard criteria) * others as indicated by fda-approved protocol exclusion criteria: * any contraindication to progesterone therapy * bmi \> 38 kg/m2 * clinically significant gynecologic pathology (for example: submucosal fibroids, abnormal uterine cavity, or others) * history of more than 1 failed fresh ivf cycles * more than 2 consecutive clinical miscarriages (gestational sac observed on ultrasound) * others as indicated by fda-approved protocol

Keywords: in vitro fertilization
safety and efficacy of twelve hours duration of mgso4 in the treatment of eclampsia in low resource setting in sudan

Conditions: Pre-Eclampsia

Summary: the investigators assume that magnesium sulphate for treating eclampsia can be safely reduced from 24 hours to shorter duration of therapeutic anticonvulsant effect for 12 hours. short duration of drug exposure is suitable for low resource setting where there is little tools or busy staff for monitoring drug toxicity.

the idea of using 12 hours duration of magnesium sulphate for treating eclampsia may be effective and attractive, especially in settings with limited resources and where there is no availability of tools to monitor the serum level of magnesium sulphate. this is because the most common reported maternal adverse effects of magnesium sulphate are minor and may be confused with other symptom of eclampsia of even labor.the administration of magnesium sulphate for 24 hours in the absence of monitoring of the serum magnesium sulphate might be life threatening in a resource- challenged situation , thus the current study is planned to be conducted to investigate the efficacy and safety of shorter duration (12 hours) of magnesium sulphate therapy in preventing development of convulsions in cases of eclampsia.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of eclampsia * must accept to participate in the study exclusion criteria: * epilepsy